FAQ: How Should Treatment Duration be Approached After Remission or Low Disease Activity in SLE?
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
FAQ: How Should Treatment Duration be Approached After Remission or Low Disease Activity in SLE?
-
Narrated by:
-
By:
In this FAQ video, Heather Finlayson, PA-C, discusses how treatment duration should be approached after achieving remission or low disease activity in systemic lupus erythematosus (SLE). As treatment options continue to expand and more patients achieve sustained disease control, questions about when and how to taper therapy have become increasingly important.
This educational discussion reviews current guideline recommendations for long-term lupus management, including the ongoing role of hydroxychloroquine, strategies for minimizing corticosteroid exposure, and considerations for tapering immunosuppressive therapies after sustained remission. Heather also explores the challenges of determining when treatment reduction may be appropriate, as biologic therapies become more widely used in lupus care.
Watch now to learn more about maintaining remission, reducing treatment burden, and the evolving approach to long-term disease management in SLE. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.
